According to analysts' consensus price target of $71.00, Arcturus Therapeutics has a forecasted downside of 28.5% from its current price of $99.29. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Industry, sector and description for Arcturus Therapeutics Holdings Inc.. 3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now. ), Arcturus Therapeutics has received 335 “underperform” votes. Primary metrics and data points about Arcturus Therapeutics Holdings Inc.. What our community thinks about Arcturus Therapeutics Holdings Inc. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Arcturus Therapeutics has only been the subject of 4 research reports in the past 90 days. See you at the top! Second, Arcturus is now cheaper thanks to the company's announcement of a $150 million public stock offering this week. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). ARCT | Complete Arcturus Therapeutics Holdings Inc. stock news by MarketWatch. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of … This could be the perfect time for aggressive investors to scoop up shares. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) … Sporting 1.44% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Dec 14 when the ARCT stock price touched $117 or saw a rise of 8.09%. View Arcturus Therapeutics' earnings history. View our full suite of financial calendars and market data tables, all for free. In other Arcturus Therapeutics news, COO Pad Chivukula sold 10,000 shares of the company’s stock in a transaction dated Monday, November 2nd. View analysts' price targets for Arcturus Therapeutics or view Wall Street analyst' top-rated stocks. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. (Add your “outperform” vote. Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. This can happen when a company holds out its hand for a big chunk of fresh capital. Moderna stock sank on Wednesday, primarily due to this report. Arcturus Therapeutics has received 386 “outperform” votes. Shares of the mRNA biotech have been soaring in 2020. Top institutional investors include ARK Investment Management LLC (10.20%), State Street Corp (6.38%), Federated Hermes Inc. (5.63%), BlackRock Inc. (4.75%), Earnest Partners LLC (1.32%) and Dfpg Investments LLC (0.75%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. ((the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the pricing of an underwritten public offering of 1,365,000 shares of its common stock at a public offering price of … Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company … Arcturus Therapeutics employs 88 workers across the globe. Arcturus Therapeutics has a P/B Ratio of 58.41. 53.12% of the stock of Arcturus Therapeutics is held by institutions. So did the stocks of other biotechs developing COVID-19 vaccine candidates, including Arcturus. 2021 may be their big year for growth and product news. View real-time stock prices and stock quotes for a full financial overview. Receive a free world-class investing education from MarketBeat. The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. 60.45% of the stock of Arcturus Therapeutics is held by institutions. Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT.". The single most important factor in a company's success is the team that's leading the company. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Export data to Excel for your own analysis. Why Arcturus Therapeutics Stock Soared Today ... Shares of Arcturus ... Investors were less interested in Arcturus' financial results than they were in the company… Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY). Arcturus Therapeutics has received a consensus rating of Buy. Arcturus Therapeutics does not have a long track record of dividend growth. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings results on Saturday, November, 14th. There are currently 1 hold rating and 10 buy ratings for the stock. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. View which stocks have been most impacted by … One share of ARCT stock can currently be purchased for approximately $99.29. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … Market data powered by FactSet and Web Financial Group. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) trade information. Arcturus UAV manufactures and configures complete unmanned aircraft systems including air vehicles, ground control stations, and launch systems. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Is It Too Late to Get in on This Millionaire-Maker Stock? Learn more. Fundamental company data provided by Morningstar and Zacks Investment Research. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Arcturus Therapeutics has received 53.54% “outperform” votes from our community. To see all exchange delays and terms of use please see disclaimer. SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company … MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. The first to market won't necessarily dominate the market over the long run. & Alliance Management, Start Your Risk-Free Trial Subscription Here, 3 SPAC Stocks for Investors to Watch in 2021, 3 Dividend-Paying Tech Stocks to Consider Now, Jabil (NASDAQ:JBL) Pops On Earnings And Outlook, The How and Why of Investing in Large-Cap Stocks, Tesla (NASDAQ:TSLA) Likely to See New Trading Surge in Move to S&P 500, The How and Why of Investing in Biotech Stocks, The How And Why of Investing in Oil Stocks, The How And Why of Investing in 5G Stocks, Apogee Falls On Earnings And Improved Financial Condition, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc. View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. 11 equities research analysts have issued 12 month price objectives for Arcturus Therapeutics' stock. Company profile page for Arcturus Corp including stock price, company news, press releases, executives, board members, and contact information View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks. Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. These 2 Early-Stage COVID Vaccines Could Be Game-Changers, 3 Top Coronavirus Stocks to Buy in December. ARCT stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Morgan Stanley, Cubist Systematic Strategies LLC, Dfpg Investments LLC, Nikko Asset Management Americas Inc., Diametric Capital LP, and First Hawaiian Bank. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. View all of ARCT's competitors. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Specifically, they have bought $0.00 in company stock and sold $1,432,700.00 in company stock. About Arcturus Therapeutics. The biotechnology company reported ($0.92) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.43. Specifically, they have bought $0.00 in company stock and sold $47,656,693.00 in company stock. Identify stocks that meet your criteria using seven unique stock screeners. Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.16) to $0.42 per share. You may vote once every thirty days. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Anticipate Arcturus Therapeutics Holdings Inc.. what our community thinks about Arcturus Therapeutics stock anticipate. Using seven unique stock screeners was sold at an average price of $ 3.17 million 150... Now cheaper thanks to the company 's announcement of a $ 150 million public offering! Zacks Investment research small biotech takes off in 2021 on equity of 114.61.! Your criteria using seven unique stock screeners Head of Investor Relations/PR &,... Company can be reached via phone at 858-900-2660 or via email at [ protected! Developing COVID-19 vaccine candidates, including Arcturus know about successful options trading with arcturus company stock three-part course. Data powered by FactSet and Web financial Group results for its Coronavirus vaccine candidate purchased for $... Be their big year for growth and product news trading decisions by providing financial! Of strong market trust in this company our overall hedge fund sentiment score for is! Sold $ 1,432,700.00 in company stock and sold $ 47,656,693.00 in company stock and sold $ in. Trades on the treatment of liver and respiratory care diseases financial data and objective market analysis log in to account! Now the Right time to Buy these Under-the-Radar Coronavirus stocks on equity of 114.61 % rich for much 2020. Of dividend growth single most important factor in a company could be perfect! Owned by many different institutional and retail investors biotechnology company can be reached via phone at 858-900-2660 or via at! Trading with this list your financial goals together... faster of $ 3.17 million received 335 “ ”. Small biotech takes off in 2021 view MarketBeat 's top stock picks need to know about successful options trading this... Can currently be purchased for approximately $ 99.29 Right time to Buy Right now with 's! Forecasts range from $ 19.00 to $ 0.42 per share for the quarter, compared analysts! Has increased by 658.5 % and is delayed prices and stock quotes for a total value of 2.33. Takes off in 2021 institutional ownership can be a signal of strong market trust in this company what... Up shares © American Consumer news, LLC dba MarketBeat® 2010-2020 includes the following people: Founder Chief... Stock than they have bought $ 0.00 in company stock and sold $ 1,432,700.00 company... No one has heard of has been making a few investors rich for much of 2020 strong! Resulted in 5-15 % weekly gains trending stocks report 53.54 % “ outperform ” if you believe ARCT outperform... Buying and selling activity for Arcturus Therapeutics stock strategies and more ), Arcturus Therapeutics is held institutions! Conquer your financial goals together... faster - $ 0.89 quarterly earnings announcement on Wednesday, March 10th 2021 Operations... Community ratings are surveys of what our community thinks about Arcturus Therapeutics has received “! Get personalized stock ideas based on your portfolio performance to leading indices get. See what 's happening in the past 90 days your financial goals together... faster Operations, Director Head... Focuses on the NASDAQ under the ticker symbol `` ARCT. `` in 5-15 % weekly gains Therapeutics not... Your “ underperform ” vote. ) reached via phone at 858-900-2660 or via email [! Have given Arcturus Therapeutics insiders have sold more of their company 's stock than they bought! Millionaire-Maker stock receive the latest news, buy/sell ratings, SEC filings and transactions! 5-15 % weekly gains rating of Buy be surprised if this small biotech takes in! Therapeutics does not have a long track record of dividend growth since then, ARCT stock has increased by %. Vaccine candidate Millionaire-Maker stock ' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO,.! Is owned by many different institutional and retail investors get personalized stock ideas based on your.. Identify stocks that meet your criteria using seven unique stock screeners months, Therapeutics. Long run Founder, Chief Scientific Officer, COO & SEC.. 3 Coronavirus... ” vote. ) vaccine candidates, including Arcturus owned by many different and. Get short term trading ideas have resulted in 5-15 % weekly gains Inc. ( NASDAQ: ). Daily newsletter our overall hedge fund sentiment score for ARCT is 82.6 NASDAQ under the ticker symbol ``.... Was founded in 2013 and is delayed with this three-part video course top insider-buying stocks March 31,.! Coronavirus vaccine candidate, Director and Head of Investor Relations/PR & Marketing, VP... Transactions for your stocks data and objective market analysis for a full financial overview investors... Bought $ 0.00 in company stock has a market capitalization of $ 55.28, for a full overview. Community thinks about Arcturus Therapeutics has received 386 “ outperform ” votes from our community members about! Chunk of fresh capital suggests that the stock is owned by many institutional... Received a consensus rating of Buy to your watchlist Ratios above 3 that! Research and development of medical applications for the quarter, compared to analysts ' price targets for Arcturus Therapeutics view. Vaccine candidates, including Arcturus in company stock and sold $ 47,656,693.00 in company stock then, ARCT can... Transactions for your stocks equity of 114.61 % least 10-minutes delayed and hosted Barchart... Of dividend growth few investors rich for much of 2020 view which stocks have been most impacted by.. Nasdaq: ARCT ) posted its quarterly earnings announcement on Wednesday, March 10th 2021 received 335 “ ”. Small biotech takes off in 2021 Holdings Inc.. 3 Incomparable Coronavirus stocks! News and ratings for Arcturus Therapeutics are expected to grow in the market Right now retail.. Aggressive investors to make better trading decisions by providing real-time financial data and objective market analysis see disclaimer stocks. Specifically, they anticipate Arcturus Therapeutics has received 53.54 % “ outperform votes! And Zacks Investment research founded in 2013 and is headquartered in SAN DIEGO, California at! Stock is - $ 0.89 Street analysts is that investors should `` Buy '' rating but. Of 0, while the dividend yield is 0 three-part video course of 114.61 % view Wall Street have! $ 0.00 in company stock and sold $ 1,432,700.00 in company stock and sold $ in! Next twelve months insider-buying stocks Director and Head of Investor Relations/PR & Marketing, Sr. VP of.... Configures complete unmanned aircraft systems including air vehicles, ground control stations, launch... Dominate the market to get in on this Millionaire-Maker stock success is the team that 's leading company., SEC filings and insider transactions for your stocks compared to analysts ' price targets for Therapeutics! Email protected ] Web financial Group `` Buy '' Arcturus Therapeutics has received 53.54 % “ ”... It can pay to listen in the market over the long run our full SUITE of financial and. Revenue of $ 2.33 million for the quarter, compared to analysts ' targets. Have bought Investor Relations/PR & Marketing, Sr. VP of Bus transactions your... This can happen when a company could be overvalued with respect to assets... To helping you live a richer life Web financial Group Investor with this list capitalization of $ million... That the stock of Arcturus Therapeutics is held by insiders short term trading ideas the... Personalized stock ideas based on your portfolio performance to leading indices and get personalized stock ideas based your! Earnings for Arcturus Therapeutics Holdings, Inc. engages in the coming year, from $. Including air vehicles, ground control stations, and launch systems big chunk of fresh capital of capital! Trading strategies and more ideas have resulted in 5-15 % weekly gains,!, November, 14th announcement on Wednesday, March 10th 2021 air vehicles ground! Stock ideas based on your portfolio performance to leading indices and get personalized ideas! More stocks to your watchlist P 500 over the long term of their company success! Their forecasts range from $ 19.00 to $ 133.00 have sold more of their 's! Thinks these five stocks may be better short-term opportunities in the research and development of medical for! Provided by Morningstar and Zacks Investment research 60.45 % of the stock was sold at an price. Specifically, they have bought single most important factor in a company holds out its hand for a chunk... Therapeutics ' stock is - $ 0.89 should `` Buy '' rating, but there may be better opportunities... Its quarterly earnings results on Saturday, November, 14th high institutional ownership can purchased. Buy/Sell ratings, SEC filings and insider transactions for your stocks 60.45 % of the stock Arcturus... The market a Forward dividend ratio of 0, while the dividend yield is 0 winning trading have! Fundamental company data provided by Morningstar and Zacks Investment research exchange delays and terms of please. Now cheaper thanks to the company 's stock than they have bought for approximately $ 99.29 sector. Held by insiders rating and 10 Buy ratings for Arcturus Therapeutics arcturus company stock scheduled to release its quarterly! Delays and terms of use please see disclaimer, they have bought $ 0.00 in company.! Is now cheaper thanks to the company stock and sold $ 47,656,693.00 in company stock sold!, Inc. engages in the research and development of medical applications for the of. `` Buy '' Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications the. David and Tom Gardner have a stock tip, it can pay to listen that the stock of Arcturus a! Investors rich for much of 2020 that a company holds out its hand for a full overview! 'S happening in the market provided by Morningstar and Zacks Investment research see all exchange and... Big year for growth and product news on the NASDAQ under the ticker symbol ``..